DJIA 17,678.70 6.10 0.03%
NASDAQ 4,771.76 13.88 0.29%
S&P 500 2,057.09 5.27 0.26%
market minute promo

GlaxoSmithKline (NYSE: GSK)



company name or ticker
Company Photos
(Click to zoom)

Is GlaxoSmithKline plc's Monster Dividend Worth the Risk?

GlaxoSmithKline has had a rotten 2014, leading to a dramatic downturn in its share price. Can this high-yielding dividend stock rebound in 2015?

NewLink and Merck Get a $30M Contract for Ebola Candidate - Analyst Blog

NewLink and Merck Get a $30M Contract for Ebola Candidate - Analyst Blog

Pharma Stocks Could Be in Deep Trouble in 2015. Here's Why.

Costly new drugs have driven pharma stock prices to all-time highs over the last two years. Here's why this trend might come to a screeching halt.

Update: Ligand Announces Key Regulatory Submissions

Sector Dividend Leader Dogs Display 26.5% To 187.3% December Upsides

The Newest FDA-Approved Obesity Drug Is Also the Oldest

Novo Nordisk gains FDA approval for Saxenda, which is already approved as an obesity treatment called Victoza.

Novartis' Alcon's Travatan Obtains Label Expansion in the EU - Analyst Blog

BioCryst Rises on Positive Ebola Candidate Results - Analyst Blog

3 Pharma Giants Growing Significantly Faster Than GlaxoSmithKline PLC

GlaxoSmithKline is a common retirement holding, but there are three other big pharma stocks growing significantly faster that investors could choose from.

’Tis the season for buying stocks dumped for tax reasons

See More Articles...